clinical trials

See the following -

In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers

Matthew Herper | Forbes | January 30, 2014

Drug companies tend to be secretive, to say the least, about studies of their medicines. For years, negative trials would not even be published. Except for the U.S. Food and Drug Administration, nobody got to look at the raw information behind those studies. The medical data behind important drugs, devices, and other products was kept shrouded. Read More »

In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers

Matthew Herper | Forbes Magazine | January 30, 2014

Today, Johnson & Johnson JNJ +0.07% is taking a major step toward changing that, not only for drugs like the blood thinner Xarelto or prostate cancer pill Zytiga but also for the artificial hips and knees made for its orthopedics division or even consumer products. “You want to know about Listerine trials? They’ll have it,” says Harlan Krumholz of Yale University, who is overseeing the group that will release the data to researchers.

Read More »

Integrating EHRs to Clinical Research EDC Systems

It has been a longstanding challenge to integrate patient data from EMRs (Electronic Medical Record systems) with EDC (Electronic Data Capture) systems for clinical studies and trials...These hurdles have been so high that the task has rarely been attempted in earnest, let alone accomplished in any significant way.  That is until recently.  How are these challenges being overcome today?  What changes have allowed this integration to be to considered and implement today? The answer is: lots!

Read More »

Introducing OpenClinica Participate

I’d like to introduce our upcoming product, OpenClinica Participate, a tool tightly integrated with OpenClinica for engaging patients and collecting data directly from study participants. If you took OpenClinica's recent survey, you got a glimpse of what your forms for patient-reported outcomes could look like in OpenClinica Participate. Driven by a powerful forms engine based on proven open-source technology, the participant forms are simple, dynamic, mobile-focused, and platform-independent. But it’s about a lot more than mobile-friendly forms.

Read More »

J&J Sets Drug Data Free In ‘YODA’ Collaboration With Yale

Drew Armstrong | Bloomberg | January 31, 2014

Johnson & Johnson (JNJ) will give academics access to data on clinical trials, a move that may prompt more companies to do the same. Read More »

J&J, Roche And Others Back Tech Platform To Bolster Translational Drug Research

Ryan McBride | FierceBiotechIT | April 10, 2013

Pharma experts and academics have joined forces to support an existing platform for managing digital translational research data, and their efforts could boost the plodding pace of drug research. The tranSMART Foundation incorporated as a nonprofit last week to organize the open source effort, Roche's ($RHHBY) Michael Braxenthaler, who serves as co-CEO of the foundation, told FierceBiotech IT. Read More »

Joel Mewton

Joel Mewton is the Chief Technology Officer (CTO) of Bitscopic, a healthcare-focused data, analytics and product company. Joel manages Bitscopic’s infrastructure, charts the company’s technological roadmap, and generally just takes care of what needs to be done.

Read More »

K&L Consulting Services, Inc. Of Fort Washington, PA Selects OpenClinica Enterprise Clinical Trial Software

Press Release | K&L Consulting Services, LLC, OpenClinica, LLC | February 13, 2013

K&L looks to leading commercial open source player to support its growing global CRO practice. Read More »

Leveraging the "Learning Health Community" Concept in Education

This idea of an iterative engaged learning environment (we can call it a “Learning Health Community”) is not far-fetched. Such a system would require quality evidence-based data and information delivered in real-time based on the real-world experiences of millions of patients. As new verified information and data develop, these would be incorporated and then deployed. We would harness the power of existing and future knowledge in a form that is usable by both medical professionals and the patients they serve. The questioning fathers and others similarly situated could access the Internet for augmented and personalized health information.

LivingMatrix Launches Practitioner Research Network to Expand and Advance Published Evidence Base for Functional Medicine

Press Release | LivingMatrix | May 24, 2018

Cloud-based Health Information Technology Company Launches Preeminent Research Network in the Field of Personalized and Functional Medicine...LivingMatrix, a health information technology company dedicated to broadening access to functional medicine by enhancing the operating efficiency of practitioners, today announced the launch of the LivingMatrix Practitioner Research Network (LM-PRN), a practice-based research network developed to advance the study and research of functional approaches to chronic disease. The LM-PRN allows practitioners to be efficiently matched with research organizations based on study needs and applies standardized outcome measures to further build the published evidence base for the application of functional medicine in the treatment of chronic disease.

Read More »

Mainstreaming ME Research: The 8th Invest In ME International ME Conference, 2013

Mark Berry | Phoenix Rising | June 2, 2013

Mark Berry reports from London on the 8th Invest in ME International ME Conference. Read More »

Many Antidepressant Studies Found Tainted by Pharma Company Influence

Roni Jacobson | Scientific American | October 21, 2015

The latest study, published in the Journal of Clinical Epidemiology, which evaluated 185 meta-analyses, found that one third of them were written by pharma industry employees. “We knew that the industry would fund studies to promote its products, but it’s very different to fund meta-analyses,” which “have traditionally been a bulwark of evidence-based medicine,” says John Ioannidis, an epidemiologist at Stanford University School of Medicine and co-author of the study. “It’s really amazing that there is such a massive influx of influence in this field.”

Read More »

Minimizing Legal Liability Or Upholding The Mission? - The Markingson Case Redux

Roy M. Poses | Health Care Renewal | March 15, 2013

There are new, and troubling developments in the long running case of Dan Markingson, the psychiatric patient and research subject who committed suicide while enrolled in a trial of anti-psychotic drugs at the University of Minnesota nearly 10 years ago. Read More »

MyClinicalTrialsLocator - A new Information Portal for Patients

Staff Writer | Channel NewsAsia | May 2, 2013

A US doctor has created a website to make it easier for the world's sickest people to connect with research that could potentially save their lives. Read More »

New Drugs Trail Many Old Ones In Effectiveness Against Disease

Sharon Begley | Reuters | June 3, 2013

Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago. Read More »